Not medical advice. Talk to your provider before using any peptide.
Full disclaimerWeight Loss Protocols
Peptide Schedule Research Team
GLP-1 agonist titration protocols for appetite suppression and metabolic support.
Semaglutide
FDA-standard weekly titration from 0.25mg to 2.4mg over 16+ weeks. Hold current dose for an extra 4 weeks if GI side effects are severe.
Tirzepatide
FDA-standard weekly titration from 2.5mg to 15mg. Many maintain at 7.5-10mg without reaching max dose.
Retatrutide
Phase 3 trial protocol: weekly titration from 1mg to 12mg. Retatrutide is a triple GLP-1/GIP/Glucagon agonist. In the Phase 3 TRIUMPH-1 trial, 12 mg produced a mean 25.0% weight loss at 80 weeks, vs 3.9% on placebo (PMID 42814954).
Semaglutide
Semaglutide at 0.025-0.05mg weekly, roughly 1/10th the standard starting dose. Dr. Tyna Moore's philosophy: "Dose up to appetite control, not suppression." Exact microgram dose is not publicly verified; the approach and philosophy come from multiple interviews including Ben Greenfield Life. She treats GLP-1 as scaffolding for building metabolic habits, not a permanent prescription.
Semaglutide + Tirzepatide
Peter Attia prescribes GLP-1 agonists clinically and flagged the lean mass loss problem early: 39% of weight lost in the STEP 1 trial was lean tissue. His protocol follows standard FDA titration (0.25mg to 1mg+ weekly) but pairs it with resistance training and 1g protein per pound of bodyweight. This is a prescriber's perspective, not personal biohacking. DEXA scans and metabolic panels required.
Tirzepatide
Three weeks, then done. Johnson tried tirzepatide at 0.5mg weekly (1/5th the standard starting dose) and halted when his data turned negative: resting heart rate up 3bpm, HRV down 7 points, sleep quality down 10%. He already had optimal metabolic markers, so the risk outweighed any benefit. This is some of the best-documented peptide discontinuation data available, with exact biomarker numbers attached.
Weight loss peptide protocols center on GLP-1 receptor agonists — peptides that reduce appetite, slow gastric emptying, and improve insulin sensitivity. These protocols use gradual dose titration over weeks to months, starting low and increasing to minimize gastrointestinal side effects.
Semaglutide (Ozempic/Wegovy) is the most studied, with FDA-approved titration from 0.25mg to 2.4mg weekly. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors for potentially greater weight loss. Retatrutide, a triple agonist still in Phase 3 trials, adds glucagon receptor activity.
All GLP-1 protocols require patience — titrating too fast causes nausea, vomiting, and diarrhea. Most users hold at each dose for 4 weeks before increasing. Many maintain at a mid-range dose rather than pushing to the maximum.
Pick a peptide, set doses, export the calendar.
Start a Weight Loss protocol